Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Opinions and Price Targets for Albemarle NYSE ALB

Elaine Mendonca by Elaine Mendonca
January 29, 2024
in Breaking News
0
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

As of January 29, 2024, analysts have expressed a range of opinions regarding Albemarle (NYSE: ALB). Over the past month, there have been 24 Buy Ratings, 11 Hold Ratings, and 3 Sell Ratings. The average 12-month price target stands at $168.85, with a high estimate of $308.00 and a low estimate of $128.00. This suggests a decline of 21.07% compared to the previous average price target of $213.92.

Analysts have recently made various adjustments to their ratings and price targets, including upgrades and downgrades. With input from 20 Wall Street analysts, the consensus rating for Albemarle is currently classified as a Moderate Buy. Based on the average price target provided by these analysts, the stock is expected to experience an upside of 31.86%.

Taking into account the most recent analyst estimates, Albemarle has received an Average Recommendation of Overweight and an Average Target Price of $163.47, based on 29 ratings.

ALB Stock Analysis: Mixed Performance and Potential Bearish Trend in January 2024

On January 29, 2024, ALB stock had a mixed performance based on the available data from CNN Money. The stock was trading near the bottom of its 52-week range and below its 200-day simple moving average, indicating a potential bearish trend.

The price of ALB shares had a slight increase of $1.39 since the market last closed, representing a rise of 1.17%. The stock closed at $119.84, suggesting a positive sentiment among investors. However, in pre-market trading, the stock experienced a drop of $0.89, which could indicate some volatility and uncertainty in the market.

Trading near the bottom of its 52-week range suggests that ALB stock has been struggling to gain momentum and reach higher price levels. This could be a result of various factors, such as weak market conditions, company-specific issues, or overall investor sentiment towards the industry.

Additionally, trading below its 200-day simple moving average indicates that the stock’s long-term trend might be bearish. The 200-day moving average is a commonly used technical indicator that helps identify the overall direction of a stock’s price movement. When a stock is trading below this moving average, it suggests a potential downward trend.

Investors should closely monitor ALB stock’s performance to determine whether the drop in pre-market trading is a temporary setback or a sign of a more significant downward trend. Factors such as company news, industry trends, and market conditions can all influence the stock’s future performance.

It is important for investors to conduct thorough research and analysis before making any investment decisions. Consulting with a financial advisor or utilizing various technical and fundamental analysis tools can help investors gain a better understanding of ALB stock’s potential risks and rewards.

ALB Stock Performance on January 29, 2024: Impressive Revenue and Income Growth, but Recent Quarter Shows Decline

ALB Stock Performance on January 29, 2024:

Total revenue:
– One-year period leading up to January 29, 2024: $7.32 billion (increase of 119.96% compared to previous year)
– Most recent quarter (Q3) compared to previous quarter: $2.31 billion (no change)

Net income:
– Past year: $2.69 billion (increase of 2074.96% compared to previous year)
– Most recent quarter: $302.53 million (decrease of 53.46% compared to previous quarter)

Earnings per share (EPS):
– Past year: $22.84 (increase of 2051.82% compared to previous year)
– Most recent quarter: $2.57 (decrease of 53.46% compared to previous quarter)

Conclusion: ALB experienced significant growth in total revenue, net income, and EPS compared to the previous year. However, the most recent quarter saw a decline in these key financial indicators. Investors should monitor ALB’s future financial reports for a better understanding of the company’s financial health.

Tags: ALB
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Checkpoint Therapeutics Announces Registered Direct Offering to Support Corporate Initiatives

Food Retailers Trading online

Analyst Ratings and Price Targets for Dollar Tree DLTR Reflect Diverse Opinions

Finance_Accounting

Dingdongs Groundbreaking 20 Million Share Repurchase Program

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com